How Epigenetic Changes in hMLH1 Connect Lab Research With Diagnosis in Gastric Cancer

Plain-language summary

This study aims to link laboratory research with the diagnostic process by examining epigenetic changes in the MLH1 gene in gastric cancer. It enrolls patients who underwent surgery for stage I-IV gastric cancer and were assessed for the MMR complex (MLH1, PMS2, MSH2, MSH6). This non-phase study is currently recruiting.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Active, not recruiting

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Start date

9/1/2024

Estimated completion

12/31/2026

Countries

Italy

Related genes

Locations

• Rome, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Patients who underwent elective gastrectomy for Stage I-IV gastric cancer.
* Surgery performed at the General Surgery Unit of Fondazione Policlinico Universitario A. Gemelli IRCCS.
* Procedures conducted between January 2017 and August 2023.
* Only patients who have already undergone immunohistochemistry evaluation for expression of the components of the MMR complex (MLH1, PMS2, MSH2, and MSH6).

Exclusion Criteria:

\- Patients with missing immunohistochemistry evaluation for the expression of the components of the MMR complex (MLH1, PMS2, MSH2, and MSH6).